Cocrystal Pharma director Phillip Frost buys $9,816 in stock By Investing.com

Phillip Frost, a director and 10% owner of Cocrystal Pharma, Inc. (), purchased shares of the company’s common stock on August 5, 2026.

Dr. Frost acquired 10,000 shares at a weighted average price of $0.9816 per share, with individual transaction prices ranging from $0.972 to $0.9898. The total value of this purchase amounted to $9,816. These shares are held indirectly by Frost Gamma Investments Trust, for which Dr. Frost serves as trustee. Following this transaction, Dr. Frost, through Frost Gamma Investments Trust, beneficially owns 1,993,551 shares of Cocrystal Pharma common stock.The timing of Dr. Frost’s purchase appears notable, as the stock has surged 25.6% over the past week, now trading at $1.03. According to InvestingPro analysis, the stock is currently overvalued relative to its Fair Value estimate, placing it among companies on the Most Overvalued list. InvestingPro offers 8 additional tips for COCP subscribers, with earnings scheduled for August 17.

Dr. Frost disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest. Additionally, this report does not include securities owned directly by OPKO Health, Inc., where Dr. Frost is Chairman of the Board and Chief Executive Officer, as he does not hold voting and investment control over those securities.

In other recent news, Cocrystal Pharma has announced the appointment of James Sapirstein as its new Chief Executive Officer. This decision was formalized in a recent SEC filing and press release. Sapirstein’s appointment is effective immediately, and he will also join the company’s Board of Directors. He replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Lee will transition to the role of Chief Scientific Officer, while Martin will continue as Chief Financial Officer. Under his employment terms, Sapirstein will receive an initial annual base salary of $265,000. He is also eligible for an annual performance bonus equal to 50% of his base salary, contingent on meeting specific performance targets set by the board. These developments mark a significant leadership change at Cocrystal Pharma.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.